La Cheim Short-Term Residential Therapeutic Program (Browning House)

Located in San Pablo, CA, La Cheim Short-Term Residential Therapeutic Program (Browning House) operates within the CA regulatory framework as a licensed addiction-treatment provider. The specific care levels offered by La Cheim Short-Term Residential Therapeutic Program (Browning House) should be confirmed directly with the admissions team. Structural evaluation of this facility's clinical posture requires review of state licensing records, accreditation status, and payer-network contracts.

Care levels at La Cheim Short-Term Residential Therapeutic Program (Browning House)

Care-level specifics for La Cheim Short-Term Residential Therapeutic Program (Browning House) are not well-documented in the public SAMHSA record; a direct conversation with the admissions team is the reliable way to confirm what the facility actually provides. Operational prerequisite for admission: documented clinical assessment establishing medical necessity for the specific level of care La Cheim Short-Term Residential Therapeutic Program (Browning House) provides. The ASAM Criteria 4e framework is the benchmark standard for this assessment and is referenced in most major payer medical-necessity documents.

Insurance and payment

Payment and insurance specifics for La Cheim Short-Term Residential Therapeutic Program (Browning House) are not fully documented in the SAMHSA registry — a direct admissions conversation is the reliable way to confirm what forms of payment are accepted and at what network-contract level. The operational prerequisite for admission is written documentation of: (a) network contract status; (b) prior authorization; (c) cost-sharing structure; (d) medical-necessity criteria applied. Absence of any of these four increases the probability of post-admission financial disagreement.

Before you call

Pre-admission due-diligence for La Cheim Short-Term Residential Therapeutic Program (Browning House): (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via CA behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether La Cheim Short-Term Residential Therapeutic Program (Browning House) offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.